MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Sofinnova Partners SAS
Finance & Acquisition: Sofinnova Partners
Parents
Sofinnova Partners SAS
Children
*Portfolio Companies: Sofinnova
2017: Its shareholders, co-led by Atlas Venture and Sofinnova Partners
2019: Amplyx has raised more than $118 million from investors, including a $67 million Series C financing round in 2017 led by Sofinnova Venture Partners.
2020: Financing co-led by seed investor Sofinnova Partners and incoming investor AbbVie, with additional investment from JDRF T1D Fund and several Italian investors
2020: Investors include Pfizer Ventures, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Schroders Adveq
2020: Matrix Capital Management, Citadel fund Surveyor Capital led the financing, along with Adage Capital Management, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, and s earlier investors—Arix, Sofinnova, Decheng Capital, Pappas Capital, and Takeda.
2020: Series A led by Sofinnova Partners, Lightstone Ventures, SV Health Investors, Takeda Ventures and Astellas Venture Management.
2021: Investors in the firm have invested at least $140 million in equity investment and include Abingworth Bioventures, Fidelity, Longitude Venture Partners, Sofinnova Venture Partners, Ares Trading, Citadel, KPCB (Kleiner Perkins) and GV (Google Ventures).
2021: The combined company came equipped with $73 million from a group of investors that included Sofinnova Partners, Droia Ventures, Polaris Partners, Novo Holdings and the venture arm of Sanofi.
2024: Capstan also has major institutional investors who participated in its latest fundraising round, including Forbion, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, OrbiMed, Polaris Partners and Vida Ventures.
2024: Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona
2024: The financing round was led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners, with participation from other top tier investors including 5AM Ventures, DCVC Bio, F-Prime Capital, GV (Google Ventures), Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, T. Rowe Price, Wellington Management, Alexandria Venture Investments, Casdin Capital, Menlo Ventures and Wilson Sonsini Goodrich & Rosati.
Aerie’s venture capital backers include TPG Ventures, Alta Partners and Sofinnova Ventures.
Also participating were Menlo Park-based Sofinnova Ventures inc., Chicago-based ARCH Venture PartnersbizWatch ARCH Venture Partners Latest from The Business Journals Sorbent raises M for heart failure drugBay Area transplant Sorbent Therapeutics raises MBa
CoreValve - Investors and Funding History:Apax Partners, Healthcap Venture Capital, Maverick Capital, Sofinnova
Existing investors include Sofinnova Ventures, InterWest Partners, Thomas McNerney & Partners
Existing investors that participated in the round include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Science
Got its early backing from Vantage Point Venture Partners, Sofinnova Ventures, Caxton Advantage Life Sciences Fund, HBM BioCapital, and others.
Intellikine has raised $41 million from a group of leading investors, including Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, Abingworth, U.S. Venture Partners, Fintech Global Capital and Biogen Idec.
Investors included Novo A/S, RA Capital, Adage Capital, Sofinnova Ventures, Alta Partners, Devon Park Bioventures, 3×5 Special Opportunity Fund, Salem Partners, and RiverVest
Its previous investors include Ann Arbor’s EDF Ventures, France’s Fund for Strategic Investment, Sofinnova Partners, HealthCap,
Johnson & Johnson Innovation, Pfizer Venture Investments, Sofinnova Partners
Participants include Abbott Biotech Ventures, Neomed and Sofinnova Partners.
Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt and
Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.
Participants include Sofinnova Partners, Morningside Ventures, Scottish Venture Fund and Alida Capital International.
Series B led by Kleiner, Perkins, Caufield and Byers (KPCB), and FinTech Global Capital, Sofinnova Ventures, Versant Ventures, Interwest Partners and Prism VentureWorks.
The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.
The funds come from Partner Capital, Sofinnova, BroadPeak, HealthCap, Innoven, Edbi and other individuals.
The Wellcome Trust led the round of financing and was joined by other existing investors including Healthcare Venture, Sofinnova Partners, and Aberdare Ventures as well as new investor, MedImmune Ventures, Inc. Read more: Press Release: Sequoia Pharmaceuti
This round was led by Sofinnova Partners, which becomes the largest investor,with strong support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth LLP.
Jumps
Key People: Sofinnova Partners
Organization & Developments: Sofinnova Partners